When evaluating overall survival, no significant difference was found between patients with and without CTCs (Figure 3a, p-value 0. stage, 39/52 (73.1%) late stage and 3/4 (75%) unstaged patients (p-value < 0.001). CTC counts ranged from 0-149 CTCs/ml with stage III/IV patients exhibiting significantly higher mean counts (41.3 CTCs/ml) than stage I/II patients (6.0 CTCs/ml) and benign patients (0 CTCs/ml, p-value = 0.001). A positive correlation between CTC count and CA-125 level was observed (Spearman correlation coefficient r = 0.309, p-value = 0.035). Kaplan-Meier curves revealed a significant decrease in disease-free survival in patients with detectable CTCs (median survival 15.0 months vs. 35.0 months, log-rank p-value = 0.042). Tumor grade and tumor histology did not influence CTC detection. == Conclusions == Invasive CTCs can be detected in a majority of epithelial ovarian malignancy patients and may predict shorter disease-free survival. Furthermore, higher CTC counts may reflect later stage disease and higher CA-125 levels. == Introduction == Ovarian malignancy is the second most commonly diagnosed gynecologic malignancy and the leading cause of death from a gynecologic malignancy in the United States [1]. One reason that ovarian malignancy is so lethal is because over 75% of cases are stage III/IV by the time of diagnosis. The preponderance of advanced stage is usually associated with poorer survival outcomes [2]. Furthermore, although a majority of optimally cytoreduced, late stage disease patients achieve a total clinical response after completing chemotherapy, most of those patients eventually relapse[3]. Thus methods that help diagnose ovarian malignancy earlier and which can detect metastasis sooner have the potential to improve survival. The idea that hematogeneous spread of ovarian malignancy could play an important role in ovarian malignancy progression was first TCS 401 free base explored in 1990 by Cain [4]. Since then, several studies have investigated the association of tumor cell detection in bone marrow with survival prognostication [5-8], however only two have evaluated the survival effect of tumor cells in peripheral blood (circulating tumor cells or CTCs) [8,9]. Marth et al’s study recognized CTCs using immunomagnetic beads conjugated to an epithelial glycoprotein (EGP-2). Samples that exhibited at least 2 TCS 401 free base cells with antibody-bound beads were considered Rabbit polyclonal to CD105 positive. Judson et al’s study used immunomagnetic beads conjugated to a mixture of epithelial markers (anti-cytokeratin 8 and 18, TFS02, CK-7, CK-10 and EGFR) to enrich tumor cells, and then used microscopic evaluation to identify and count CTCs based on specific cytoplasmic staining and tumor cell morphology. These antibody-based methods resulted in low CTC detection rates ranging from 12%-18.7%, and the presence of CTCs defined by anti-epithelial antibody markers alone was not found to affect survival or disease recurrence. Furthermore, the majority of CTCs detected in these previous studies may not have been viable since only a few CTCs retain the ability for invasive growth needed for metastatic progression [10]. In the current study, a novel cell invasion assay altered from a previously explained method [11] was used to detect viable and invasive CTCs. This method enriches CTCs based on a tumor cell’s unique ability to invade and ingest a Cell Adhesion Matrix (CAM) and distinguishes CTCs from non-tumor and non-viable cells. When blood containing CTCs is usually exposed to CAM, CTCs bind to, invade and ingest CAM, while the majority of non-tumor and lifeless tumor cells do not. If CAM is usually fluorescently labeled, TCS 401 free base fluorescence microscopic visualization of CAM fragments (CAM+) by a cell that is simultaneously co-stained with epithelial markers (Epi+) can identify a CTCin vitro. Our study evaluated the clinical characteristics and survival prognosticative value of these CAM+/Epi+ CTCs in ovarian malignancy patients. Specifically, the study aimed to: 1) determine how clinical parameters, such as disease stage, TCS 401 free base TCS 401 free base tumor grade, tumor histology and CA-125 level, affect the presence CAM+/Epi+ cells and 2) assess the association between overall and disease-free survival time and the presence of CAM+/Epi+ cells. == Materials Methods == == Patients == The study was conducted at Stony Brook University or college Hospital after approval from your Committees on Research Involving Human.